Hodgkin Lymphoma

Abstract

Overview This chapter provides a historical perspective on the marked advances in radiotherapy and chemotherapy that have contributed to significant improvements in the curability of Hodgkin lymphoma (HL) over the past several decades. The classic features and new insights into the epidemiology, biology, and pathologic characteristics of HL are described. With emphasis on the modern clinical approach to the staging, imaging, and treatment of HL, the chapter highlights how current management approaches, such as refined risk stratification, use of PET imaging, and the reduction of radiation field and dose, seek to limit long‐term toxicities of therapy while maintaining excellent cure rates. Finally, the authors describe how the development of novel, biologically targeted therapies has contributed to significant changes in the therapeutic landscape for patients with relapsed, refractory HL.